EATRIS and the importance of having strong research infrastructures
EATRIS-ERIC got a nice feature today in Health Europa, UK-based publication covering EU health policy. Read it here !
EATRIS-ERIC got a nice feature today in Health Europa, UK-based publication covering EU health policy. Read it here !

After a successful first edition (https://translational-neuroscience.b2match.io/), NeurATRIS and Medicen Paris Région are very happy to invite you to join the second edition of “Translational neuroscience: challenges and opportunities”, on January 25, 2019, in Paris.
Gathering experts in neurodegenerative diseases, this event will foster interactions between researchers, clinicians, biotech and pharmaceutical companies.
You will be able to:
Online registration is free and mandatory before January 15: https://translational-neuroscience-2019.b2match.io/
We are looking forward to seeing you there !

The 2018 EATRIS Combined Platform Meeting will be held in Ljubljana on December 11th and 12th. Like in previous years, the Platform Combined Meeting will be the moment to discuss the EATRIS platform activities and future strategies together, providing formidable networking opportunities. This year the Platform Combined Meeting will also be followed by a two-day CORBEL open workshop on the theme of public-private collaboration. This 2-day event on 12th and 13th December 2018 (back to back with the Combined EATRIS Platform meeting in Ljubljana) will focus on all relevant aspects of setting up such collaborations, from initial contacts through planning and negotiation to completion of legal agreements and project implementation.
NeurATRIS will be present, and we would be very happy to meet you there !
Neuroimaging webinars powered by EATRIS and NeurATRIS
We are pleased to announce that EATRIS and NEURATRIS are launching a series of webinars on Neuroimaging in November of this year. The series will cover the usage of CEST-MRI, optical imaging and PET imaging in neurodegenerative diseases and their potential application in translational medicine. These webinars will be brought to you by experts in the field.
All webinars will take place from 14:00-15:00 CET and are free of charge. The neuroimaging webinars include an audience Q&A session during which attendees can ask questions at the end of the lecture. Please note that all webinars will be recorded and available for later viewing.

The discovery that a set of lymphatic vessels interacts with blood vessels to remove toxic waste products from the brain has implications for cognition, ageing and disorders such as Alzheimer’s disease has been reported.
International multi-site collaboration hub will implement new clinical imaging tools and deliver several projects per year with enhanced speed and throughput
Amsterdam, The Netherlands, June 4, 2018 - The European Infrastructure for Translational Medicine (EATRIS) has formed a collaboration with GlaxoSmithKline (GSK) to deliver a clinical and scientific expert network for the development and application of innovative imaging methods for inflammatory diseases.
The iPEPS innovation accelerator and Scientist.com are launching a call for biotech startups developing a novel therapeutic and/or diagnostic approach with a main focus on central nervous system (CNS) diseases (neuro-oncology, psychiatry, neurological disorders or preventive health).
Apply now until July 16th, and get awarded:
The winner of this competition and the runner-up will be announced at the end of September and will benefit of iPEPS mentoring to fast track the development of their projects in one of the most thriving research and innovation ecosystem in Paris.

Accumulation of amyloid-β (Aβ) peptides in the brain is a critical early event in the pathogenesis of Alzheimer's disease (AD), the most common age-related neurodegenerative disorder. There is increasing interest in measuring levels of plasma Aβ since this could help in diagnosis of brain pathology. However, the value of plasma Aβ in such a diagnosis is still controversial and factors modulating its levels are still poorly understood.
The 12th annual international partnering conference BioEurope Spring will take place March 12-14, 2018, in Amsterdam.
With a focus on European innovation and global collaboration, BIO-Europe Spring is the premier springtime partnering conference bringing together a “whoʼs who” from biotech, pharma and finance in the most innovative biopharma clusters in Europe.
Ali Aït-Ikhlef, NeurATRIS business development manager, will be there: This email address is being protected from spambots. You need JavaScript enabled to view it.and meet him there !
NeurATRIS launches a call aimed at fostering collaborative projects between NeurATRIS members and scientific community (academic and clinical laboratories and biotech companies) involved in neurodegenerative disease projects with a grant up to 50 000 € for the successful applicants.
Academic research laboratories and biotechs are welcome to apply. Applicant consortia may include a private partner, but only academics and biotechs will be eligible for funding.
First edition of “Translation Neurosciences” is over but you can still have access to the event…
NeurATRIS at BioFIT 2017 (28 -29 November 2017, Strasbourg)
NeurATRIS will be participating to BioFIT convention on November 28-29, 2017, in Strasbourg, the leading partnering event in Europe for technology transfer, academia-industry collaborations and early-stage innovations in the field of Life Sciences.
From October 7 to 15, 2017, come to the fête de la science ! Come experiment, visit laboratories, increase your taste for science, chat with researchers everywhere in France. All events are free and organized for broad audiences of every age. A unique opportunity for the younger ones to discover science and maybe future vocations.
In particular, you can discover the activities of NeurATRIS researchers in several of our labs:
Registrations for the first edition of « Translational neuroscience : challenges and opportunities » are now open !
NeurATRIS and Medicen Paris Région are very happy to invite you to this event on November 20, 2017, at the Cité Universitaire Internationale de Paris.
Gathering experts in neurodegenerative diseases, this event will foster interactions between researchers, clinicians, biotech and pharmaceutical companies.
You will be able to:
Online registration is free and mandatory before November 5 : https://tranlational-neuroscience.b2match.io/
Looking forward to seeing you there !

NeurATRIS and Medicen Paris Région are very happy to invite you to the first edition of “Translational neuroscience: challenges and opportunities”, on November 20, 2017, at the Cité Universitaire Internationale de Paris.
Gathering experts in neurodegenerative diseases, this event will foster interactions between researchers, clinicians, biotech and pharmaceutical companies.
You will be able to:
Looking forward to seeing you there !


The European Research Infrastructure for Translational Medicine (EATRIS) organizes its third bi-annual conference, “Translational Medicine 2017” on September 24-26 2017 at Corinthia Hotel in Prague.
This event, open to a wide range of stakeholders from academic researchers, funders to industry players and regulators, will bring together international experts to discuss the latest advancements in translational medicine.
The theme of this third edition, “Enhancing Predictivity in Medicines Development” will focus on bringing together the latest technologies to increase success in drug development, from novel in vitro systems to new biomarkers or clinical trial methodology for patient selection and stratification.
For this year’s edition, you will hear from – among others – Mark Schmidt (Senior Director, Janssen Research and Development), Philip Murphy (Head, Experimental Medicine Imaging, GSK), Christopher Austin (NIH-NCATS, United States). Find out all about the conference’s keynote speakers.
The programme also includes a pre-conference day on Sunday, September 24, that will be dedicated to a series of educational workshops tackling topics in the field such as molecular imaging, biomarker validation or potency assays for ATMP’s and vaccines.
Translational Medicine 2017 also welcomes abstract submissions until May 15, 2017!
For more information, please visit: www.translationalmedicine2017.eu
Questions? Send an email to: This email address is being protected from spambots. You need JavaScript enabled to view it.
NeurATRIS will attend this event, do not hesitate to This email address is being protected from spambots. You need JavaScript enabled to view it.us to set up a meeting.
Cognitive decline is one of the most debilitating manifestations of disease progression in Parkinson's disease and is a key determinant of a patient's quality of life and independence.1 The ability to predict and to manage this complication is highly relevant for recruitment into and stratification of clinical trials, particularly those designed to slow disease progression and to prevent dementia. Although a multitude of drugs for Parkinson's disease is available to improve motor aspects of the disease, these do not have a major effect on cognitive decline.
The authors of a study published in The Lancet Neurology aimed to develop a clinical–genetic score to predict global cognitive impairment in patients with the disease. This international study involving clinicians from AP-HP, Inserm, UPMC at ICM was conducted using 9 cohorts gathering 3200 patients. The resulting predictive algorithm provides a potential test for future cognitive health or impairment in patients with Parkinson's disease. This model could improve trials of cognitive interventions and inform on prognosis.
In France, the DIG-PD cohort, coordinated by Pr Jean-Christophe Corvol at ICM, followed more than 400 patients for 6 years.
NeurATRIS will be participating to RegMed Europe on July 7, 2017, in Paris, the first european matchmaking event on regenerative medicine.
Participants will get information about the ongoing regenerative medicine challenges and topics, learn about the major European ecosystems, get the chance to present their innovative projects, and meet the European actors in their field to build international partnerships.
Main topics:
You will be able to meet our business developper, Ali AIT-IKHLEF, who can tell you more about NeurATRIS assets to work alongside in your translational projects in the Neuroscience field for the characterization of neurodegenerative diseases.
Do not hesitate to This email address is being protected from spambots. You need JavaScript enabled to view it.us to set up a meeting.
NeurATRIS
NeurATRIS is pleased to announce that we will be participating to « Médecine Translationnelle au service de l’innovation Thérapeutique : Enjeux, Besoins et Opportunités » (13th June, Paris)
The goal of this day is to provide an overview of translational medicine platforms of key account (academic and pharmaceutical industries) in order to understand how they work, their needs and their roles in the value chain of discovery and development of therapeutic solutions.
This is a unique opportunity to hear P. HANTRAYE, NeurATRIS director, and learn more about NeurATRIS assets to work alongside in your translational projects in the Neuroscience field for the characterization of neurodegenerative diseases.
Do not hesitate to contact us to set up a meeting.
NeurATRIS
On the occasion of World Multiple Sclerosis day, on May 31st, the french magazine "Sciences et Avenir" dedicates an article to promising recent work from Catherine Lubetzki's team at the Brain and Spine Institute (ICM) in Paris.
Several studies from the team have shown the importance of the remyelination process in patient health state. In its most frequent form, multiple sclerosis is indeed charaterized by inflammatory bursts in the central nervous system (brain and spine), followed by respite periods during which myelin is partially rebuilt.
New imaging techniques developped at ICM, more precise than MRI, allowed to show that this reparation "potential" differs a lot among patients : by injecting a specific tracer that fixes on myelin, before performing a PET scan, the degree of myelin degradation can be measured.
You can find the complete article (in French) on the magazine website.
NeurATRIS is pleased to announce that we will be participating to Bio-Europe Spring (20th – 22nd March, Barcelona)
BIO-EUROPE SPRING is the premier springtime partnering conference bringing together a “whoʼs who” from biotech, pharma and finance in Europe's most innovative biopharma clusters.
This is a unique opportunity to learn more about NeurATRIS assets to work alongside in your translational projects in the Neuroscience field for the characterization of neurodegenerative diseases.
Do not hesitate to This email address is being protected from spambots. You need JavaScript enabled to view it. to set up a meeting.
NeurATRIS
Multiple sclerosis is an inflammatory disease of the nervous central system leading to a progressive destruction of the myelin sheath surrounding the axons, essential for their protection and for the transmission of the nerve impulse. Bruno Stankoff and Catherine Lubetzki’s team developed a cutting-edge imaging technique which makes possible to visualize neuron demyelination and remyelination and to quantify their degeneration. These results, published in Annals of Neurology, open the way to better treatment for patients and to the evaluation of novel remyelination therapies.